Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

8.865
+0.1551.78%
Volume:95.91M
Turnover:839.32M
Market Cap:102.14B
PE:22.32
High:8.890
Open:8.580
Low:8.520
Close:8.710
52wk High:10.720
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:0.83
T/O Rate:0.83%
Dividend:0.29
Dividend Rate:3.27%
EPS(LYR):0.397
ROE:20.90%
ROA:10.70%
PB:2.32
PE(LYR):22.32
PS:2.79

Loading ...

CSPC Pharma's Paliperidone Palmitate Injection Receives Market Approval

Stock News
·
Jul 24

CSPC Pharma Wins China Approval for Paliperidone Palmitate Schizophrenia Injection

Reuters
·
Jul 24

CSPC Pharmaceutical - Paliperidone Palmitate Injection Receives Marketing Approval

THOMSON REUTERS
·
Jul 24

CSPC Pharmaceutical Group Stock Rises 2.2% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jul 24

Movement Alert|CSPC PHARMA Rises 3.23% in Regular Trading, Therapeutic mRNA Vaccine Enters Phase II Clinical Trial

Market Focus
·
Jul 24

CSPC Pharma Starts Phase 2 Trial of HPV Therapeutic Vaccine in China

MT Newswires Live
·
Jul 23

CSPC Pharma Launches Phase II Trial of mRNA Vaccine SYS6026 for HPV16/18-Related Cervical HSIL

Bulletin Express
·
Jul 22

CSPC Pharmaceutical Group Stock Slips 1.1% in Hong Kong

Dow Jones
·
Jul 21

CSPC Pharmaceutical Group Stock Rallies 4.9% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jul 20

Movement Alert|CSPC Pharmaceutical Rises 3.21% in Regular Trading, First ADC Drug Application Accepted Amid Sector Recovery

Market Focus
·
Jul 20

CSPC Pharma's Application for Breast Cancer Drug Candidate Accepted in China

MT Newswires Live
·
Jul 17

CSPC Pharmaceutical’s Trastuzumab Envedotin NDA Accepted by China’s NMPA

Bulletin Express
·
Jul 17

CSPC Pharma's New Drug Application for Envituzumab Injection Accepted by Chinese Regulator

Stock News
·
Jul 17

CSPC Pharmaceutical - Nmpa Accepts New Drug Application for Trastuzumab Envedotin Injection

THOMSON REUTERS
·
Jul 17

CSPC Pharmaceutical - Product Indicated for Unresectable or Metastatic Her2-positive Breast Cancer in Adults

THOMSON REUTERS
·
Jul 17

Movement Alert|CSPC Pharmaceutical Falls 3.02% in Regular Trading, Trading at HKD 8.22

Market Focus
·
Jul 17

CSPC Pharma Begins Two Drug Trials in China

MT Newswires Live
·
Jul 16

CSPC PHARMA Initiates Phase II Trial in China for Novel Sirolimus Formulation in Rare Vascular Tumor

Stock News
·
Jul 16

CSPC PHARMA's Phase III Trial for SYS 6043 in Platinum-Resistant Gynecologic Cancers Commences at First Chinese Site

Stock News
·
Jul 16

CSPC Pharmaceutical Initiates China Phase II Trial of Albumin-bound Sirolimus Injection for Epithelioid Haemangioendothelioma

Reuters
·
Jul 16